Core Viewpoint - KBR, Inc. experienced a significant decline in share price following the cancellation of a $20 billion contract with the U.S. Department of Defense's TRANSCOM, raising concerns about the company's previous positive statements regarding the contract's status [1][3][4]. Group 1: Contract Details - KBR's HomeSafe Alliance joint venture was awarded a contract in November 2021 to manage household goods for U.S. Armed Services and DoD civilians, valued at up to $20 billion over nine years [4]. - The contract aimed to centralize and improve the relocation process for military families, representing a major partnership with TRANSCOM [4]. Group 2: Company Communications - KBR's leadership expressed confidence in the contract's status, describing the partnership as "strong" and "excellent" during a May 2025 investor call, asserting a commitment to the program's success [5]. - Despite these assurances, operational issues were reportedly mounting behind the scenes, contradicting the company's public optimism [5][8]. Group 3: Contract Termination - On June 19, 2025, TRANSCOM terminated the HomeSafe contract due to failures in fulfilling obligations, including chronic delays and complaints about damaged goods [6]. - The termination shocked investors, especially given KBR's recent positive communications about the contract [7]. Group 4: Investigation and Legal Implications - Following the contract cancellation, Hagens Berman initiated an investigation into whether KBR misled investors regarding the contract's status [2][9]. - The firm is encouraging affected investors to report their losses and is seeking information from individuals with knowledge of the situation [2][9].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Landstar System, Inc. due to allegations of federal securities law violations and unlawful business practices following a significant supply chain fraud revelation [1][3]. Group 1: Company Overview - Landstar System, Inc. (NASDAQ:LSTR) is facing scrutiny after announcing a significant supply chain fraud that may impact its earnings per share for the first quarter of 2025 by $0.35 to $0.50 [3]. - The company withdrew its previously issued earnings guidance for the first quarter of 2025 due to the fraud [3]. Group 2: Investor Impact - Following the announcement of the fraud, Landstar's stock experienced a decline, which was exacerbated by the company's inability to file its quarterly report on time due to ongoing evaluations of accounting and internal control matters related to the fraud [3]. - Investors who purchased Landstar shares and suffered losses are encouraged to contact Bragar Eagel & Squire for potential legal recourse [1][4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen's statements regarding PGN-EDO51 were materially false and misleading [3]. - Specific allegations include that PGN-EDO51 was less effective and safe than claimed, and that the phase two CONNECT2 study was dangerous or deficient for FDA approval [3]. - As a result of these issues, it is claimed that PepGen was likely to halt the CONNECT2 study, and the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated [3]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action by the deadline of August 8, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price following the announcement of a clinical hold by the FDA [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and the clinical trial protocol, including the risk of Serious Adverse Events (SAEs) [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of a clinical hold by the FDA due to a SAE, including a participant's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [4]. - Shareholders who register will receive updates on the case's status through a portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for alleged violations of securities laws, specifically for making false and misleading statements regarding its financial agreements and business practices [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Tempus exaggerated the value of several agreements, including transactions with affiliated entities and internally financed deals [2]. - Concerns have been raised about a joint venture with SoftBank, which may be perceived as "round-tripping" funds to inflate revenue [2]. - The acquisition of Ambry by Tempus is highlighted, noting Ambry's reputation for aggressive and potentially unethical business conduct, which further undermines the credibility of Tempus's public statements [2]. Group 2: Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through balanced counseling and aggressive advocacy [3]. - The firm represents some of the largest hedge funds and alternative asset managers, indicating a strong focus on high-value litigation claims [3].

Company Overview - Quantum Corporation is a data storage and management company that specializes in technology for unstructured data, including backup, archiving, and high-performance storage systems for video and large-scale data environments [3] Allegations and Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Quantum, stemming from allegations of providing potentially misleading business information to investors [1] - On June 30, 2025, Quantum announced it would be unable to meet the filing deadline for its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, due to a review of accounting related to certain revenue contracts and the application of standalone selling price under applicable accounting standards [4] - Following this announcement, Quantum's stock price fell by up to 15% during after-hours trading on June 30, 2025 [4]

Group 1 - KBR, Inc. is under investigation by Bragar Eagel & Squire, P.C. for potential violations of federal securities laws and unlawful business practices [1] - On June 20, 2025, KBR announced that its joint venture, HomeSafe Alliance, had its role in the Global Household Goods Contract terminated by U.S. Transportation Command, leading to a significant stock price drop of $3.85 per share, or 7.29%, closing at $48.93 [2] - The law firm is reaching out to KBR stockholders who may have suffered losses and is encouraging them to participate in the investigation [3] Group 2 - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in complex litigation across state and federal courts [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) ...

Core Viewpoint - KBR, Inc. experienced a significant decline in share price following the cancellation of a major contract with the U.S. Department of Defense, raising concerns about potential misrepresentation of the contract's status to investors [1][4][5]. Group 1: Contract Details - KBR's joint venture, HomeSafe Alliance LLC, was awarded a contract valued at $20 billion with a potential term of 9 years to manage household goods for the U.S. Armed Services and Department of Defense [3]. - The contract was terminated by TRANSCOM due to HomeSafe's failure to meet obligations, which included issues like delays and damaged items [4][5]. Group 2: Investor Reactions and Investigations - Following the contract cancellation announcement, KBR's share price fell by $3.85, or 7.3%, on June 20, 2025 [5]. - Hagens Berman, a national shareholders rights firm, has initiated an investigation into KBR for possible violations of securities laws related to prior positive statements about the contract [2][5]. Group 3: Company Assurances - As recently as May 6, 2025, KBR management expressed confidence in the contract's status, claiming a strong relationship with TRANSCOM [4][7]. - However, just weeks later, it was revealed that HomeSafe had been struggling with various challenges related to the contract, contradicting KBR's earlier assurances [5].

Core Viewpoint - Hims & Hers Health, Inc. experienced a significant share price drop of over 30% following the termination of its collaboration with Novo Nordisk due to concerns regarding sales practices and marketing of the weight loss drug Wegovy® [1][4]. Company Summary - Hims & Hers Health, Inc. had previously partnered with Novo Nordisk to provide access to Wegovy®, which is FDA-approved for obesity treatment, through its platform [3]. - The partnership was short-lived, as Novo Nordisk cited "illegal mass compounding and deceptive marketing" as reasons for the termination [4]. - Hims & Hers had previously assured investors of its regulatory compliance, claiming it was not bypassing the regulatory process [2]. Investigation Summary - Hagens Berman, a national shareholders rights firm, has initiated an investigation into potential violations of securities laws by Hims & Hers, urging affected investors to report their losses [2]. - The investigation will focus on whether Hims & Hers misled investors regarding the marketing of potentially unsafe versions of Wegovy® [4].